Neurocrine Biosciences
Neurocrine Biosciences, Inc. is an American biopharmaceutical enterprise that discovers, develops, and commercializes pharmaceutical products for neurological and endocrine disorders. The company directs its research focus toward complex diseases affecting the central nervous system and endocrine pathways. Its principal products encompass FDA-approved therapeutics for the treatment of tardive dyskinesia, chorea associated with Huntington's disease, and congenital adrenal hyperplasia. Revenue is driven primarily through the commercial sale of proprietary pharmaceutical products within domestic healthcare markets. The primary end markets comprise neurological and psychiatric patients treated by specialized healthcare practitioners and hospitals. As an established biotechnology enterprise in neuroscience, the firm holds a notable position in specialty therapeutics. Headquartered in San Diego, California, Neurocrine Biosciences Inc. is publicly listed on NASDAQ under the ticker symbol NBIX.
47 of the funds FundTelligence covers report a position in Neurocrine Biosciences.
- Legal name
- Neurocrine Biosciences Inc.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 47
Funds holding Neurocrine Biosciences
- BNP Health Care Innovators — BNP Paribas · 3.45 % (full portfolio disclosed, June 2026)
- DNB Bioteknologi — DNB · 3.44 % (full portfolio disclosed, September 2026)
- DNB Health Care — DNB · 2.18 % (full portfolio disclosed, September 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 1.45 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.17 % (full portfolio disclosed, October 2026)
- JPM America Equity Fund — JPM · 1.17 % (full portfolio disclosed, June 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 1.08 % (full portfolio disclosed, October 2026)
- Swedbank Robur Small Cap USA — Swedbank · 0.95 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 47 funds holding it.